ARTICLE | Product Development
ICER’s influence on payers could translate to a seat at the table for government drug reviews
ICER’s focus on value-based pricing has positioned it to be a major voice on drug pricing in the U.S., whoever wins the election
October 31, 2020 12:55 AM UTC
As its influence grows among payers and biopharmas, ICER should have a role to play in most price regulation scenarios that play out under the next administration, regardless of who’s at the helm.
Whether the Institute for Clinical and Economic Review (ICER) takes an official consultancy role, serves as an external reference point or becomes a government agency itself, its position as the emerging de facto health technology assessment (HTA) agency in the U.S. is pretty secure for the coming years, according to payers and pricing consultants interviewed by BioCentury. ...